Tumor-targeted synergistic blockade of MAPK and PI3K from a layer-by-layer nanoparticle

Clinical Cancer Research

Volumn 21, Issue 19, 2015, Pages 4410-4419

  Dreaden, Erik C ^a,b   Kong, Yi Wen ^a   Morton, Stephen W ^a,b   Correa, Santiago ^a,b   Choi, Ki Young ^a,b   Shopsowitz, Kevin E ^a,b   Renggli, Kasper ^a,b   Drapkin, Ronny ^c,d   Yaffe, Michael B ^a,b,e   Hammond, Paula T ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; CREATININE; HERMES ANTIGEN; MITOGEN ACTIVATED PROTEIN KINASE; NANOPARTICLE; PHOSPHATIDYLINOSITOL 3 KINASE; SELUMETINIB; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PROTEIN KINASE INHIBITOR;

ALBUMIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BIOLUMINESCENCE; BREAST CARCINOMA; CANCER CELL; CELL KILLING; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG TARGETING; ENCAPSULATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; HYDROPHILICITY; HYDROPHOBICITY; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; INTRACELLULAR TRANSPORT; LIVER TOXICITY; MOUSE; NON SMALL CELL LUNG CANCER; NONHUMAN; PARTICLE SIZE; PH; PHARMACOLOGICAL BLOCKING; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SURFACE PROPERTY; TISSUE DISTRIBUTION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GROWTH; TUMOR SPHEROID; TUMOR VOLUME; WESTERN BLOTTING; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DISEASE MODEL; DRUG EFFECTS; DRUG POTENTIATION; DRUG SCREENING; FEMALE; METABOLISM; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; FEMALE; HUMANS; MICE; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; NANOPARTICLES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTEIN KINASE INHIBITORS; SIGNAL TRANSDUCTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84945581336     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-15-0013     Document Type: Article

References (60)

1. Moxley JH, De Vita VT, Brace K, Frei E. Intensive combination chemotherapy and X-irradiation in Hodgkin's disease. Cancer Res 1967;27:1258-63.
2. De Vita VJr, Simon R, Hubbard S, Young R, Berard C, Moxley J III, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980;92:587-95.
3. Corcoran R, Cheng K, Hata A, Faber A, Ebi H, Coffee E, et al. Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models. Cancer Cell 2013;23:121-8.
4. Basu S, Harfouche R, Soni S, Chimote G, Mashelkar RA, Sengupta S. Nanoparticle-mediated targeting of MAPK signaling predisposes tumor to chemotherapy. Proc Nat Acad Sci U S A 2009;106:7957-61.
5. Sengupta S, Eavarone D, Capila I, Zhao G, Watson N, Kiziltepe T, et al. Temporal targeting of tumour cells and neovasculature with a nanoscale delivery system. Nature 2005;436:568-72.
6. Pandey A, Kulkarni A, Roy B, Goldman A, Sarangi S, Sengupta P, et al. Sequential application of a cytotoxic nanoparticle and a PI3K inhibitor enhances antitumor efficacy. Cancer Res 2014;74:675-85.
7. Hegde G, de la Cruz C, Chiu C, Alag N, Schaefer G, Crocker L, et al. Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer. Sci Transl Med 2013;5:171ra18.
8. Deng ZJ, Morton SW, Ben-Akiva E, Dreaden EC, Shopsowitz KE, Hammond PT. Layer-by-layer nanoparticles for systemic codelivery of an anticancer drug and siRNA for potential triple-negative breast cancer treatment. ACS Nano 2013;7:9571-84.
9. Blanco E, Sangai T, Wu S, Hsiao A, Ruiz-Esparza GU, Gonzalez-Delgado CA, et al. Colocalized delivery of rapamycin and paclitaxel to tumors enhances synergistic targeting of the PI3K/Akt/mTOR Pathway. Mol Ther 2014;22:1310-9.
10. Johnson N, Li Y-CC, Walton ZE, Cheng KA, Li D, Rodig SJ, et al. Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition. Nat Med 2011;17:875-82.
11. Lee Michael J, Ye Albert S, Gardino Alexandra K, Heijink Anne M, Sorger Peter K, MacBeath G, et al. Sequential application of anticancer drugs enhances cell death by rewiring apoptotic signaling networks. Cell 2012;149:780-94.
12. Morton SW, Lee MJ, Deng ZJ, Dreaden EC, Siouve E, Shopsowitz KE, et al. A nanoparticle-based combination chemotherapy delivery system for enhanced tumor killing by dynamic rewiring of signaling pathways. Sci Signal 2014;7:ra44.
13. Frei E. Curative cancer chemotherapy. Cancer Res 1985;45:6523-37.
14. Ma L, Kohli M, Smith A. Nanoparticles for combination drug therapy. ACS Nano 2013;7:9518-25.
15. Caruso F, Caruso RA, Mohwald H. Nanoengineering of inorganic and hybrid hollow spheres by colloidal templating. Science 1998;282:1111-4.
16. Donath E, Sukhorukov GB, Caruso F, Davis SA, Möhwald H. Novel hollow polymer shells by colloid templated assembly of polyelectrolytes. Angew Chem Int Ed 1998;37:2201-5.
17. Shutava TG, Balkundi SS, Vangala P, Steffan JJ, Bigelow RL, Cardelli JA, et al. Layer-by-layer-coated gelatin nanoparticles as a vehicle for delivery of natural polyphenols. ACS Nano 2009;3:1877-85.
18. Schneider G, Decher G. From functional core/shell nanoparticles prepared via layer-by-layer deposition to empty nanospheres. Nano Lett 2004; 4:1833-9.
19. Zahr A, de Villiers M, Pishko M. Encapsulation of drug nanoparticles in selfassembled macromolecular nanoshells. Langmuir 2005;21:403-10.
20. Agarwal A, Lvov Y, Sawant R, Torchilin V. Stable nanocolloids of poorly soluble drugs with high drug content prepared using the combination of sonication and layer-by-layer technology. J Controll Release 2008; 128:255-60.
21. Poon Z, Chang D, Zhao X, Hammond PT. Layer-by-Layer Nanoparticles with a pH-Sheddable layer for in vivo targeting of tumor hypoxia. ACS Nano 2011;5:4284-92.
22. Poon Z, Lee JB, Morton SW, Hammond PT. Controlling in vivo stability and biodistribution in electrostatically assembled nanoparticles for systemic delivery. Nano Lett 2011;11:2096-103.
23. Hammond PT. Polyelectrolyte multilayered nanoparticles: using nanolayers for controlled and targeted systemic release. Nanomedicine 2012;7:619-22.
24. Dreaden EC, Morton SW, Shopsowitz KE, Choi J-H, Deng ZJ, Cho N-J, et al. Bimodal tumor-targeting from microenvironment responsive hyaluronan layer-by-Layer (LbL) nanoparticles. ACS Nano 2014;8:8374-82.
25. Sebolt-Leopold J, Herrera R. Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 2004;4:937-47.
26. Vivanco I, Sawyers C. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2:489-501.
27. Johnson L, Mercer K, Greenbaum D, Bronson R, Crowley D, Tuveson D, et al. Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature 2001;410:1111-6.
28. Shaw AT, Winslow MM, Magendantz M, Ouyang C, Dowdle J, Subramanian A, et al. Selective killing of K-ras mutant cancer cells by small molecule inducers of oxidative stress. Proc Natl Acad Sci USA 2011; 108:8773-8.
29. Davies H, Bignell G, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002;417:949-54.
30. Salmena L, Carracedo A, Pandolfi P. Tenets of PTEN tumor suppression. Cell 2008;133:403-14.
31. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
32. Tuveson D, Shaw A, Willis N, Silver D, Jackson E, Chang S, et al. Endogenous oncogenic K-ras(G12D) stimulates proliferation and widespread neoplastic and developmental defects. Cancer Cell 2004;5:375-87.
33. Engelman JA, Chen L, Tan X, Crosby K, Guimaraes AR, Upadhyay R, et al. Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med 2008;14:1351-6.
34. Janku F, Lee J, Tsimberidou A, Hong D, Naing A, Falchook G, et al. PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers. PLoS ONE 2011;6:e22769.
35. Carracedo A, Pandolfi P. The PTEN-PI3K pathway: of feedbacks and crosstalks. Oncogene 2008;27:5527-41.
36. Serra V, Scaltriti M, Prudkin L, Eichhorn P, Ibrahim Y, Chandarlapaty S, et al. PI3K inhibition results in enhanced HER signaling and acquired ERK dependency in HER2-overexpressing breast cancer. Oncogene 2011;30: 2547-57.
37. Cen B, Mahajan S, Wang W, Kraft A. Elevation of receptor tyrosine kinases by small molecule AKT inhibitors in prostate cancer is mediated by Pim-1. Cancer Res 2013;73:3402-11.
38. Carracedo A, Ma L, Teruya-Feldstein J, Rojo F, Salmena L, Alimonti A, et al. Inhibition of mTORC1 leads to MAPK pathway activation through a PI3Kdependent feedback loop in human cancer. J Clin Invest 2008;118: 3065-74.
39. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007;316:1039-43.
40. Straussman R, Morikawa T, Shee K, Barzily-Rokni M, Qian Z, Du J, et al. Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion. Nature 2012;487:500-4.
41. Wee S, Jagani Z, Xiang KX, Loo A, Dorsch M, Yao Y-M, et al. PI3K pathway activation mediates resistance to MEK inhibitors in KRAS mutant cancers. Cancer Res 2009;69:4286-93.
42. Castellano E, Sheridan C, Thin M, Nye E, Spencer-Dene B, Diefenbacher M, et al. Requirement for interaction of PI3-Kinase p110α with RAS in lung tumor maintenance. Cancer Cell 2013;24:617-30.
43. Murillo MM, Zelenay S, Nye E, Castellano E, Lassailly F, Stamp G, et al. RAS interaction with PI3K p110α is required for tumor-induced angiogenesis. J Clin Invest 2014;124:3601-11.
44. Posch C, Moslehi H, Feeney L, Green G, Ebaee A, Feichtenschlager V, et al. Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo. Proc Natl Acad Sci U S A 2013;110:4015-20.
45. Shimizu T, Tolcher AW, Papadopoulos KP, Beeram M, Rasco DW, Smith LS, et al. The clinical effect of the dual-targeting strategy involving PI3K/AKT/mTORand RAS/MEK/ERK pathways in patients with advanced cancer. Clin Cancer Res 2012;18:2316-25.
46. Du Page M, Dooley AL, Jacks T. Conditional mouse lung cancer models using adenoviral or lentiviral delivery of Cre recombinase. Nat Prot 2009;4:1064-72.
47. Borisy AA, Elliott PJ, Hurst NW, Lee MS, Lehár J, Price ER, et al. Systematic discovery of multicomponent therapeutics. Proc Natl Acad Sci U S A 2003;100:7977-82.
48. Wancket LM, Meng X, Rogers LK, Liu Y. Mitogen-activated protein kinase phosphatase (Mkp)-1 protects mice against acetaminophen-induced hepatic injury. Toxicol Pathol 2012;40:1095-105.
49. Chen Z, Cheng K, Walton Z, Wang Y, Ebi H, Shimamura T, et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 2012;483:613-20.
50. Yang Y, Iwanaga K, Raso MG, Wislez M, Hanna AE, Wieder ED, et al. Phosphatidylinositol 3-Kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-Induced lung cancer. PLoS ONE 2008;3:e2220.
51. Morton S, Poon Z, Hammond P. The architecture and biological performance of drug-loaded LbL nanoparticles. Biomaterials 2013;34:5328-35.
52. Qhattal HSS, Liu X. Characterization of CD44-Mediated cancer cell uptake and intracellular distribution of hyaluronan-grafted liposomes. Mol Pharm 2011;8:1233-46.
53. Greyner HJ, Wiraszka T, Zhang L-S, Petroll WM, Mummert ME. Inducible macropinocytosis of hyaluronan in B16-F10 melanoma cells. Matrix Biol 2010;29:503-10.
54. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Comm 2013; 4:2126.
55. Hoeflich K, O'Brien C, Boyd Z, Cavet G, Guerrero S, Jung K, et al. In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. Clin Cancer Res 2009;15: 4649-64.
56. Iadevaia S, Lu YL, Morales FC, Mills GB, Ram PT. Identification of optimal drug combinations targeting cellular networks: integrating phosphoproteomics and computational network analysis. Cancer Res 2010;70: 6704-14.
57. Mirzoeva OK, Das D, Heiser LM, Bhattacharya S, Siwak D, Gendelman R, et al. Basal subtype and MAPK/ERK Kinase (MEK)-Phosphoinositide 3-Kinase feedback signaling determine susceptibility of breast cancer cells to MEK inhibition. Cancer Res 2009;69: 565-72.
58. Tian X, Azpurua J, Hine C, Vaidya A, Myakishev-Rempel M, Ablaeva J, et al. High-molecular-mass hyaluronan mediates the cancer resistance of the naked mole rat. Nature 2013;499:346-9.
59. Ngamcherdtrakul W, Morry J, Gu S, Castro DJ, Goodyear SM, Sangvanich T, et al. Cationic polymer modified mesoporous silica nanoparticles for targeted siRNA delivery to HER2+ breast cancer. Adv Funct Mater 2015;25:2646-59.
60. Schnell MA, Hardy C, Hawley M, Propert KJ, Wilson JM. Effect of blood collection technique in mice on clinical pathology parameters. Hum Gene Ther 2002;13:155-61.